Three leaders from Reven Holdings, Brian Denomme (President/COO), Peter Lange (CEO), and Michael Volk (Chief Strategy & Compliance Officer),  join Steve to discuss the latest major legal development in their ongoing fight with the SEC over the frozen assets of their once-promising drug, RJX.

A federal judge has refused to dismiss Reven’s lawsuit, instead demanding more clarity on whether the SEC’s sweeping asset freeze, which halted all company operations and research, amounts to an unconstitutional government “taking.” The ruling could have billions of dollars in implications and potentially reshape how far federal agencies can go in enforcement actions.

The Reven team shares their side of the story, how a “miracle drug” meant to save lives was stopped cold, what’s next in court, and what this fight means for innovation, investors, and patients nationwide.